Beyond a decade: a comparative study of 15-year survival rates in screen-detected vs. symptomatic breast cancer patients in Hungary
Springer Science and Business Media LLC - Trang 1-7 - 2023
Tóm tắt
Breast cancer is the leading cancer in women globally. Despite decreasing mortality rates, largely due to early detection and modern treatment, the effectiveness of screening on long-term survival outcomes remains unclear. This study evaluates the 15-year survival outcomes of a national breast cancer screening program initiated in Hungary in 2002. Using a prospectively maintained patient database, the study included individuals from the first 6 years of the program who underwent surgery for histologically confirmed breast cancer and had available follow-up information. Patients were categorized based on the method of breast cancer detection into two groups: those diagnosed during or 2 years after the population-based screening exam (Group A), and those who self-detected or sought medical attention for symptoms (Group B). Of the 309 patients who underwent breast cancer surgery, 208 were screen-detected (Group A) and 101 were symptomatic (Group B). The 15-year overall survival was 75.0% for Group A and 76.2% for Group B (p = 0.927). The 15-year disease-specific survival was 85.6% and 81.2% (p = 0.249), respectively. A statistically not significant positive trend in disease-free survival was observed in Group A (81.7% vs. 75.2%; p = 0.144). The study underscores the importance of extended follow-up periods in evaluating the outcomes of breast cancer screening programs. While the screening program may not significantly enhance overall survival rates, it has demonstrated a reduction in the mastectomy rate and could potentially extend periods of disease-free survival. These findings contribute to the ongoing discourse about the long-term benefits of breast cancer screening programs.
Tài liệu tham khảo
Sung H, Ferlay J, Siegel RL et al (2021) Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71:209–249
Arnold M, Morgan E, Rumgay H et al (2022) Current and future burden of breast cancer: global statistics for 2020 and 2040. Breast 66:15–23
World Health Organization (2014) WHO position paper on mammography screening. World Health Organization, Geneva
Toth D, Varga Z, Toth J et al (2018) Short- and long-term (10-year) results of an organized, population-based breast cancer screening program: comparative, observational study from Hungary. World J Surg 42:1396–1402
Brierley JD, Gospodarowicz MK, Wittekind C et al (2017) TNM classification of malignant tumours. 8th edn. Wiley Blackwell/John Wiley & Sons, Inc. Chichester, West Sussex, United Kingdom; Hoboken, New Jersey
Welch HG, Prorok PC, O’Malley AJ et al (2016) Breast-cancer tumor size, overdiagnosis, and mammography screening effectiveness. N Engl J Med 375:1438–1447
Ravdin PM, Cronin KA, Howlader N et al (2007) The decrease in breast-cancer incidence in 2003 in the United States. N Engl J Med 356:1670–1674
Berry DA, Cronin KA, Plevritis SK et al (2005) Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med 353:1784–1792
Tabar L, Fagerberg CJ, Gad A et al (1985) Reduction in mortality from breast cancer after mass screening with mammography. Randomised trial from the Breast Cancer Screening Working Group of the Swedish National Board of Health and Welfare. Lancet 1:829–832
Tabar L, Fagerberg G, Duffy SW et al (1989) The Swedish two county trial of mammographic screening for breast cancer: recent results and calculation of benefit. J Epidemiol Community Health 43:107–114
Tot T, Gere M, Pekar G et al (2011) Breast cancer multifocality, disease extent, and survival. Hum Pathol 42:1761–1769
Tot T, Gere M (2008) Radiological-pathological correlation in diagnosing breast carcinoma: the role of pathology in the multimodality era. Pathol Oncol Res 14:173–178
Gotzsche PC, Jorgensen KJ (2013) Screening for breast cancer with mammography. Cochrane Database Syst Rev CD001877
Independent UKPoBCS (2012) The benefits and harms of breast cancer screening: an independent review. Lancet 380:1778–1786
Ujhelyi M, Pukancsik D, Kelemen P et al (2016) Does breast screening offer a survival benefit? A retrospective comparative study of oncological outcomes of screen-detected and symptomatic early stage breast cancer cases. Eur J Surg Oncol 42:1814–1820
Autier P, Boniol M, Gavin A, Vatten LJ (2011) Breast cancer mortality in neighbouring European countries with different levels of screening but similar access to treatment: trend analysis of WHO mortality database. BMJ 343:d4411
Miller KD, Nogueira L, Devasia T et al (2022) Cancer treatment and survivorship statistics. CA: Cancer J Clin 72:409–436
Kutikov A, Weinberg DS, Edelman MJ et al (2020) A war on two fronts: cancer care in the time of COVID-19. Ann Intern Med 172:756–758
Giaquinto AN, Sung H, Miller KD et al (2022) Breast cancer statistics, 2022. CA Cancer J Clin 72:524–541